TRPC1 and Duchenne muscular dystrophy: Considering that the rAAV-MD based treatments of DMD are currently promising but would rather lead to a milder BMD-like muscular dystrophy, we evaluated the potential of TRPC1 and TRPC3 to represent alternative or complementary therapeutic targets to rAAV-MD based treatments of DMD.